Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Gains from Investment Securities (2023 - 2025)

Cardiff Oncology's Gains from Investment Securities history spans 9 years, with the latest figure at $11.2 million for Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 492.07% year-over-year to $11.2 million; the TTM value through Sep 2025 reached $11.2 million, up 492.07%, while the annual FY2025 figure was $1000.0, 99.99% down from the prior year.
  • Gains from Investment Securities for Q3 2025 was $11.2 million at Cardiff Oncology, up from $2.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $11.2 million in Q3 2025 and bottomed at $668803.0 in Q1 2025.
  • The 3-year median for Gains from Investment Securities is $4.3 million (2023), against an average of $5.1 million.
  • The largest annual shift saw Gains from Investment Securities increased 25.32% in 2024 before it surged 492.07% in 2025.
  • A 3-year view of Gains from Investment Securities shows it stood at $6.7 million in 2023, then rose by 25.32% to $8.3 million in 2024, then soared by 34.9% to $11.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Gains from Investment Securities are $11.2 million (Q3 2025), $2.0 million (Q2 2025), and $668803.0 (Q1 2025).